

Research Paper

S-Palmitoylation as a Functional Regulator of Proteins Associated with Cisplatin Resistance in Bladder Cancer

Muhammad Shahid¹, Minhyung Kim¹, Peng Jin¹, Bo Zhou¹, Yang Wang¹, Wei Yang^{1,2}, Sungyong You¹, Jayoung Kim^{1,2}✉

1. Departments of Surgery and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

2. Department of Medicine, University of California Los Angeles, CA 90095, USA.

✉ Corresponding author: Jayoung Kim, PhD. Departments of Surgery and Biomedical Sciences; Cedars-Sinai Medical Center, Davis 5071; 8700 Beverly Blvd., Los Angeles, CA 90048. Tel.: +1-310-423-7168; Fax: +1-310-967-3809; E-mail: Jayoung.kim@csmc.edu.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>). See <http://ivyspring.com/terms> for full terms and conditions.

Received: 2020.03.18; Accepted: 2020.05.02; Published: 2020.07.19

Abstract

Protein S-palmitoylation is a powerful post-translational modification that regulates protein trafficking, localization, turnover, and signal transduction. Palmitoylation controls several important cellular processes, and, if dysregulated, can lead to cancer, cardiovascular disease, and neurological disorders. The role of protein palmitoylation in mediating resistance to systemic cisplatin-based chemotherapies in cancer is currently unknown. This is of particular interest because cisplatin is currently the gold standard of treatment for bladder cancer (BC), and there are no feasible options after resistance is acquired. Using unbiased global proteomic profiling of purified S-palmitoylated peptides combined with intensive bioinformatics analyses, we identified 506 candidate palmitoylated proteins significantly enriched in cisplatin-resistant BC cells. One of these proteins included PD-L1, which is highly palmitoylated in resistant cells. Pharmacological inhibition of fatty acid synthase (FASN) suppressed PD-L1 palmitoylation and expression, which suggests the potential use of FASN-PD-L1-targeted therapeutic strategies in BC patients. Taken together, these results highlight the role of protein palmitoylation in mediating BC chemoresistance.

Key words: S-palmitoylation; lipid; lipidation; post-translational modification; tumor

Introduction

Systemic cisplatin-based chemotherapy is the current gold standard of treatment for metastatic bladder cancer (BC) [1-3]. However, acquired chemoresistance is common; thereby, limiting the usage of cisplatin. Patients who acquire chemoresistance ultimately have no further viable treatment options and their cancer usually recurs. The 5-year survival rate for BC after recurrence is approximately 15% [4-6]. As of now, there is a lack of comprehensive understanding behind the mechanisms driving cisplatin resistance. Thus, there is an unsolved and urgent need to identify a method of distinguishing which BC patients are at a higher risk of developing chemoresistance.

Metabolic reprogramming has been accepted as a hallmark of cancer [7-10]. These changes in metabolic activities may also be involved in

cisplatin-induced cell death. As a result, metabolic studies on cisplatin resistance may potentially lead to new clues for improving therapies against refractory BC. Several prior metabolomic studies found that BC may have abnormalities in metabolites involved in lipid usage [11,12]. It has also been suggested that perturbed metabolism may be implicated in cancer drug-resistance, aggressiveness, or progression [13]. Consistent with these earlier findings, our recent study suggested that alterations in acetate and lipid metabolism, which is mediated by acetyl-CoA synthetase 2 (ACSS2), an enzyme that converts acetate to acetyl-CoA, plays a role in cisplatin resistance [14]. By performing unbiased data-driven analysis, as described below, our real-time live metabolomics identified metabolic reprogramming in a series of isogenic cisplatin-sensitive and resistant BC cell lines.

In a previous study, we also found that glucose-derived endogenous acetate contributes to cell viability and increased de novo synthesis of lipids via ACSS2 [15]. However, the role of these bioactive metabolites in influencing lipid metabolism in BC cisplatin resistance is not fully understood.

Lipid modification of proteins at the post-translational level mostly occurs on cysteine thiols through the covalent addition of long-chain fatty acids (predominantly 16-carbon palmitic acid) [16,17]. This is called protein palmitoylation and can lead to an increase in hydrophobicity of cytoplasmic proteins and an affinity to cytosolic membrane surfaces [18]. Palmitoylation is an attractive mechanism for modulating protein activity, stability, interactions, localization, signaling transduction, apoptosis, and carcinogenesis [19-24]. It has been shown that palmitoylation is particularly important for protein stability; it suppresses degradation by preventing ubiquitylation [19]. The role of palmitoylation in protein stability has been demonstrated in a wide variety of targets and diseases, including c-Met, TEAD transcription factor, progressive rod-cone degeneration, and Huntington's disease [16,25-27]. Based on the critical role of palmitoylation in protein function and disease, investigating its impact on acquired chemoresistance in BC presents a promising opportunity. From our original palmitoyl-protein identification and site characterization (PalmPISC) method [28], we previously developed a low-background acyl-biotinyl exchange (LB-ABE), a significantly improved method for successful purification and identification of hydrophobic palmitoylated proteins [28,29]. By largely eliminating the co-isolation of non-palmitoylated proteins, LB-ABE minimizes the "ratio compression" issue and substantially improves quantification accuracy [29,30].

Fatty acid synthase (FASN) is a multifunctional enzyme that is involved in the de-novo synthesis of lipids [31]. Its main function is catalyzing the synthesis of 16-C palmitate [32]. Overexpression of FASN has been noted in a variety of different tumor types, including non-muscle invasive BC (NMIBC), and is significantly associated with poorer prognoses [33]. Studies have shown that FASN is a particularly informative prognostic predictor in BC; expression was found to be positively correlated with tumor aggressiveness, histologic grade, recurrence, and poor survivability in patient cohorts [34,35]. Additionally, inhibition of FASN via siRNA increased apoptosis and decreased proliferation in BC cells [36]. The primary product of FASN, palmitate, plays an especially important in protein palmitoylation by attaching to and regulating protein localization,

stability, and function [17]. Consequently, FASN is directly involved in the palmitoylation of proteins.

Current understanding of protein palmitoylation (more accurately termed S-acylation) status and its role in cisplatin resistance remains very limited. In this paper, our proteome-scale analysis of adipocyte S-acylated proteins in cisplatin-sensitive vs resistant BC cells suggest 506 putative palmitoylated proteins associated with cisplatin resistance. We also tested the hypothesis that lipid metabolism changes in cisplatin-resistant BC cells may be mediated by the S-palmitoylation of FASN. Our experimental results demonstrated that protein palmitoylation of FASN contributes to cisplatin resistance in BC cells. This study also provides evidence suggesting that FASN inhibition alters the palmitoylation of programmed death ligand-1 (PD-L1).

Materials and Methods

Cell culture

Parental T24 human BC cells were procured from American Type Culture Collection. Cisplatin-sensitive (T24S) and resistant T24 (T24R) BC cells were developed and characterized in the laboratory [37]. Cells were cultured in Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine serum, 2% glutamine, and 1% antibiotics (Invitrogen, Carlsbad, CA). All BC cells used for this paper were maintained under a humidified atmosphere of 5% CO₂ at 37 °C.

Antibodies and reagents

The following antibodies and dilutions were used according to manufacturer's instructions: β -actin (A1978) from Sigma; PD-L1 (13684) (1:1000), FASN (3180) (1:1000) and HRP-conjugated secondary antibodies, rabbit (7074) (1:3000), mouse (7076) (1:3000), from Cell Signaling Technology.

Palmitoyl-protein enrichment using LB-ABE

Palmitoyl proteins were enriched using our LB-ABE method [30]. Briefly, after cell lysis, 0.7 mg of protein from each replicate was reduced by 50 mM tris(2-carboxyethyl)phosphine (TCEP) and alkylated sequentially by 50 mM N-ethylmaleimide and 50 mM 2,2'-dithiodipyridine (DTDP). Palmitoyl proteins were converted into biotinylated proteins using 2 M neutral hydroxylamine and 1 mM biotin-N-[6-(biotinamido) hexyl]-3'-(2'-pyridyldithio) propionamide (HPDP), enriched by streptavidin affinity purification, and eluted by 50 mM TCEP.

CAPTUREome™ S-Palmitoylated Protein Kit Assay

Confirmation of S-palmitoylated proteins in BC cells was conducted using the commercially available CAPTUREome™ S-Palmitoylated Protein Kit (cat # K010-311, Badrilla, UK). Following the indicated 2-bromopalmitate (2-BP) treatments, cells were collected and washed in phosphate-buffered saline (PBS). The methodology for acyl-RAC, including blocking of free thiols, cleavage of thioester linkages, and capture of nascent thiols on Sepharose, was carried out according to the manufacturer's instructions. In particular, equal amounts of protein (1-2 mg) were diluted in 500 µl of blocking buffer (buffer A and thiol blocking reagent) and incubated at 40 °C for 4 hours with constant shaking. Three volumes of cold acetone were added, and proteins were allowed to precipitate at -20°C for 20 min. Following centrifugation of the solution at 16,000 g for 5 min, the pellet was extensively washed with 70% acetone five times and air-dried completely after the final wash. Pellet was re-dissolved in 300 µl binding buffer and incubated in a shaking heat block at 40°C for 1 hour. The homogenates were centrifuged at 16,000 × g for 5 min to remove insoluble debris. Approximately 20 µl of each supernatant was saved as the "total input." The pre-washed capture resin slurry (50 µl) was added to the remaining lysates, and 19 µl of thioester cleavage reagent was then added. Binding reactions were carried out on a rotator at room temperature for 2.5 hours. Resins were washed at least five times with binding buffer. Supernatants were removed and mixed with 2× Laemmli loading buffer, heated to 60 °C for 10 min, and separated via SDS-PAGE. All kits were used following the manufacturer's instructions.

Palmitoyl protein digestion and label-free proteomic analysis

Enriched palmitoyl proteins were digested by trypsin, using filter-aided sample preparation (FASP) [38,39]. Label-free proteomic analysis was performed using an EASY-nLC 1000 connected to an LTQ Orbitrap Elite Hybrid Mass Spectrometer, as previously described [29]. Tryptic peptides were loaded onto a 2 cm trap column and separated on a 50 cm EASY-Spray Analytical Column heated to 55 °C, using a gradient of 2-34% B in 174 min, 34-60% B in 10 min, 60-100% B in 2 min, and 100% B in 14 min at the flow rate of 150 nL/min. Mass spectra were acquired in a data-dependent manner, with automatic switching between mass spectrometry (MS) and tandem mass spectrometry (MS/MS) scans. In the MS scans, a lock mass at m/z 445.120025 was applied to provide internal mass calibration. The full scan was

performed using a 240,000 resolution at m/z 400 Th, with an ion packet setting of 1×10⁶ for automatic gain control and maximum injection time of 500 ms. The 20 most intense peptide ions with charge state ≥2 were automatically selected for MS/MS fragmentation by rapid collision-induced dissociation (rCID), using a resolution of 7,500, 1×10⁴ automatic gain control, 50 ms maximum injection time, 10 ms activation time, and 35% normalized collision energy. Dynamic exclusion was enabled with a repeat count of 1, an exclusion duration of 30 s, and a repeat duration of 90 s.

Database searching for protein identification and quantification

The acquired MS data was searched against the Uniprot_Human Database (released on 01/22/2016, containing 20,985 sequences) using the Andromeda [40] algorithm in the MaxQuant [41] (v1.5.5.1) environment. The searching parameters were set as follows: trypsin/P as the protease; oxidation (M), acetyl (protein N-term), NEM(C), and carbamidomethyl (C) as variable modifications; up to two missed cleavages; minimal peptide length as 7; mass tolerance for MS1 was 4.5 ppm for main search and for MS2 was 0.5 Da; identification of second peptides enabled; label-free quantification (LFQ) enabled, and match-between-runs within 2 min were enabled. A stringent 1% FDR was used to filter PSM, peptide, and protein identifications.

Identification of differentially palmitoylated proteins (DPPs)

LFQ intensities were normalized using the quantile normalization method [42] to compare different conditions. To filter out low-quality proteins, selected proteins were detected in at least two samples under each condition. DPPs between T24S and T24R cells were identified using a previously reported statistical test [43]. Briefly, log₂ intensities of each protein from T24R cells were compared to those in T24S cells using the Student's t-test and log₂-median ratio test. We estimated empirical null distributions of t-values and log₂-median ratio values by randomly permuting 6 samples 1,000 times and calculating the t-test and log₂-median ratio test. These two p-values were then integrated into an overall p-value using Stouffer's method [44]. DPPs were identified as proteins with overall P<0.05 and absolute log₂-fold-change ≥ 0.58.

Functional enrichment analysis

Enrichment analysis of gene ontology biological process (GOBPs) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways for DPPs was

performed using DAVID [45]. The functional classification analysis of GOBPs, gene ontology cellular components (GOCCs), and gene ontology molecular functions (GOMFs) was performed using PANTHER (Ver. 11) [46].

Reconstruction of a network model

To reconstruct a network model describing cisplatin resistance in BC cells, a subset of genes that are involved in metabolic processes was selected. Interaction information of the genes from the STRING database (Ver. 10.5) [47] was then collected and used to reconstruct a network model. Finally, the network model was visualized using Cytoscape [48]. The nodes in the network model were distributed according to the metabolic pathways that they are involved in.

Western blot analysis

Whole-cell lysates for western blot analysis were prepared as described in a previous paper [49]. T24R and T24S BC cells were cultured on 10 cm plates and treated with 2-BP or orlistat at varying doses. Cells were lysed with RIPA buffer (20 mM Tris, 150 mM NaCl, 1% Nonidet P-40, 0.1 mM EDTA) (Pierce, ThermoFisher) supplemented with a phosphatase inhibitor cocktail (ThermoFisher), homogenized, and centrifuged at 13,000 ×g and 4°C for 20 min. Afterwards, 25 µg of protein lysates per lane was run on a 4-15% gradient SDS-PAGE gel. Following protein transfer onto polyvinylidene fluoride (PVDF), the membranes were blocked with either 5% bovine serum albumin (BSA) or 5% nonfat milk in Tris-buffered saline with 0.1% Tween 20 (TBST [2.42 g/L Tris-HCl, 8 g/L NaCl, and 1 mL/L Tween 20 (pH 7.6)]) for 1 hour at room temperature. This was followed by incubation with specific primary antibodies at 4 °C overnight and 3 X 10 min washes with TBST solution. The membranes were further incubated with HRP-conjugated secondary antibodies at room temperature for 1 hour. β-actin was used as a loading control. Experiments were performed in at least triplicates for each western blot analysis.

Measurement of palmitate and cholesterol

Levels of palmitate in T24S and T24R cells were determined by targeted metabolomics analysis through the University of Florida Metabolomics Core using mass spectrometry-based targeted metabolomics analysis. Levels of cholesterol in the BC cells were determined using the commercially available Cholesterol Quantification Kit (cat #MAK043, Sigma, MO, USA). Cells were lysed in 1% (w/v) Triton X-100 in chloroform. The homogenates were centrifuged at 13,000 × g for 10 min to remove insoluble debris, and the organic phase (lower phase)

was collected and dried in a 50°C dry bath for 20 min. Samples were vacuum dried for 30 min to remove traces of chloroform. The dried lipids were resuspended via vortex in an assay buffer and further quantified. All kits were used in accordance with the manufacturer's instructions.

Cell proliferation assay

Cells were seeded at a density of 2×10⁶ cells/well in 12-well plates. Cells were then incubated with standard growth medium and treated with varying doses of 2-BP or orlistat, as described in the figures. Cells were stained with 0.05% crystal violet solution after removing the medium. After incubation at room temperature for 15 min, the wells were washed thoroughly with PBS, and cells were fixed with 4% paraformaldehyde at room temperature for 5 min. For quantitative analysis, the stained cells were dissolved in 10% acetic acid solution for reading absorbance at 570-590 nm [50]. All experiments were run in at least triplicates.

Statistical analysis

Student's t-tests were performed to evaluate differential expression of the proteins between two groups. Variables with normal distribution were expressed as mean ± standard deviation (SD). All reported p-values are two-tailed, with P<0.05 being considered as statistically significant.

Results

Palmitoyl-proteomics analysis identified DPPs associated with cisplatin resistance in BC cells

Our group previously developed and characterized isogenic human BC cell lines, cisplatin sensitive (T24S) and resistant T24 BC cells (T24R) [51]. In this study, we coupled LB-ABE enrichment with label-free proteomics to identify the potential link between protein palmitoylation and cisplatin resistance in BC. Briefly, we isolated palmitoyl-proteins from whole cell lysates by LB-ABE, digested them into peptides with trypsin using FASP, analyzed peptides by liquid chromatography-tandem mass spectrometry (LC-MS/MS), and performed database searching analysis and LFQ using MaxQuant. Our proteomics analysis workflow is summarized in **Figure 1A**. A total of 4,188 putative palmitoylated proteins were identified with a false discovery rate of ≤1%. Representative MS spectrum of FASN is shown in **Figure 1B**.

After filtering out the low-quality proteins, which are detected less than two replicates from T24S or T24R BC cells, we found that most of the palmitoylated proteins overlap in T24S and T24R cells (3,315 proteins: 89.71% of total) (**Figure 1C**). We also

identified 184 proteins that were palmitoylated only in T24R cells, not in T24S, and 196 proteins that were palmitoylated only in T24S cells, not in T24R (Figure

1C). The heatmap shows that the palmitoylation levels of most proteins in T24S and T24R cells were not significantly different (Figure 1D).




Figure 1. (A) Workflow for quantitative palmitoyl-proteomic comparison of two isogenic BC cells, T24R and T24S, using LFQ LC-MS/MS analysis following LB-ABE. After LB-ABE, a total of 16 samples (4 samples x 4 conditions) were digested in parallel into tryptic peptides by FASP, followed by LC-MS/MS. (B) Representative tandem mass spectrum of candidate palmitoyl peptide. LB-ABE-enriched proteins were separated by SDS-PAGE and digested in gel, followed by the extraction of tryptic peptides, which were analyzed by LC-MS/MS. Free cysteines in the purified peptides are candidate palmitoylation sites. (C-G) The detected palmitoylated proteins from T24R and T24S cells were classified by gene ontology categories. (C) Venn diagram shows the number of identified proteins in T24R and T24S cells. (D) Heatmap depicts abundance of commonly identified proteins in both T24R and T24S. Red and blue indicate high and low abundance of the proteins, respectively. (E-G) Pie chart visualizes the proportion of the number of proteins involved in the enriched gene ontology categories including cellular compartment (E), biological processes (F), and molecular functions (G).

Supplementary table 1 shows the 3,695 palmitoylated proteins identified in both T24S and T24R BC cells. To assess the functions of these 3,695 palmitoylated proteins, we performed functional classification analysis using PANTHER [46]. The location and function of these proteins are summarized in **Figures 1E-1G**. The identified palmitoylated proteins are functionally highly diverse; however, 35.1% of the classified proteins are

related to metabolic processes and localization (**Figure 1F**).

DPPs between T24R and T24S cells. Among the 3,695 identified proteins, at least 2,581 (70%) were previously reported to be palmitoylated in other human cells [29,52], confirming successful enrichment of palmitoyl-proteins in this study. Most of the 2,581 putative palmitoylated proteins were not reported in normal human bladder or BC cells (**Figure 2A**).




Figure 2. Known and novel palmitoylated proteins from T24R and T24S cells. (A) Pie chart depicts the proportion of palmitoylated and non-palmitoylated proteins from the total identified proteins. **(B)** Pie chart shows proportion of known and novel candidate palmitoyl-proteins. **(C-D)** Known and novel palmitoylated proteins in other cancer cells and bladder cells.

Next, we sought to identify DPPs in T24R cells compared to T24S. To further understand cisplatin resistance-associated protein palmitoylation changes, we aimed to identify DPPs between T24R and T24S cells. A statistical hypothesis test using an empirical null model was conducted (see **Methods**). From the total 3,315 putative palmitoylated proteins, 506 proteins were identified as DPPs based on the criteria of a combined $P < 0.05$ and \log_2 -transformed fold-change of 0.58 (**Figure 2B**). Furthermore, we found only 506 proteins as being differentially abundant in T24R cells compared to T24S after extensive statistical analysis. Among those identified 506 DPPs, at least 351 (69%) were identified as known palmitoyl proteins [29,52] (**Figure 2B**). To construct the database of known palmitoylated proteins, we combined the 3,593 human palmitoyl proteins compiled in the SwissPalm (v2), a compendium of palmitoyl proteins, with the 2,895 high-confidence candidate human palmitoyl proteins identified from LNCaP cells using LB-ABE to generate the currently most comprehensive palmitoyl-proteome database, containing 4,669 known palmitoyl proteins. Then, by comparing the 506 differentially abundant palmitoyl proteins with the 4,669 known human palmitoyl proteins, 351 DPPs were identified as known palmitoyl-proteins. The remaining 155 (31%) DPPs are novel putative palmitoyl-proteins and not reported in any type of cells (**Figure 2B**). A few examples of known and novel DPPs were shown in **Figures 2C and 2D**.

Cisplatin resistance-associated protein palmitoylation changes

These 506 DPPs included 180 upregulated and 326 downregulated DPPs in T24R cells, compared to T24S (**Figure 3A**). A volcano plot displays DPPs between the T24R vs. T24S cells (**Figure 3B**). Among these DPPs, NCAM1, VIM, ROR1, MAOA, and SLC7A2 are known to be palmitoylated in other types of cells[52]. **Figure 3C** summarizes the most altered known palmitoylated proteins in T24R compared to T24S cells.

Biological and mechanistic meaning of DPPs associated with cisplatin resistance

The top 10 significantly enriched biological processes suggest that carboxylic acid transport, cell-cell adhesion, and biological adhesion were enriched for by DPPs in T24R cells (**Figure 4A**). Further functional enrichment analysis of the 180 upregulated DPPs in T24R cells revealed that oxidation-reduction or lipid metabolic processes were enriched, while the 326 downregulated DPPs were enriched for anion/ion transport and apoptosis (5 out

of top 7 biological processes) (**Figure 4B**). The following doughnut charts exhibit the proportion of the numbers of up (outside) and downregulated DPPs (inside) for enriched molecular functions (**Figure 3B**) and cellular compartments (**Figure 4C**). In terms of molecular functions, those related to catalytic activity or binding were enriched for in both up and downregulated DPPs, suggesting that palmitoylation functions in membrane anchoring, trafficking, and cellular localization-associated enzymatic activity (**Figure 4D**). Cellular compartments, such as the organelles and membrane, were also enriched for by DPPs (**Figure 4E**).

Table 1 shows the enriched biological processes of DPPs between T24R and T24S cells. Functional analysis suggested that proteins related to oxidation-reduction and lipid metabolism pathways are highly palmitoylated in T24R cells. In contrast, those related to ion and anion transport were significantly downregulated in T24R cells. Collectively, our data imply that protein palmitoylation may be involved in a wide range of biological processes and aggressiveness of cancer, which can be further associated with cisplatin resistance.

Inhibition of palmitoylation differently perturbed protein palmitoylation in T24S and T24R cells

A lipid-based protein palmitoylation inhibitor, 2-BP, was used to test how palmitoylation of identified DPPs are regulated in T24R and T24S cells. In T24S cells, 165 DPPs were identified as being downregulated in response to 2-BP (\log_2 -fold-change > 0.58 , combined p -value < 0.05) (**Figure 5A**). A volcano plot exhibits the DPPs significantly altered by palmitoylation inhibition (**Figure 5B**). The enriched biological processes among downregulated DPPs indicated protein localization (**Figure 5C**), while those upregulated include intermediate filament, skin development, and fatty acid beta-oxidation. (**Figure 5A**).

In T24R cells, 75 DPPs were upregulated and 132 were downregulated by palmitoylation inhibition (\log_2 -fold-change > 0.58 , combined p -values < 0.05) (**Figure 5D**). A volcano plot exhibits up or downregulated DPPs after 2-BP treatment (**Figure 5E**). The enriched biological processes among the 132 processes downregulated by palmitoylation inhibition indicated the glycosaminoglycan metabolomic process, hippo signaling, and protein localization to the plasma membrane (**Figure 5F**); while those upregulated include epidermis development, skin development, cell junction

organization, and fatty acid beta-oxidation. (Figure S1B).

There were several clustered patterns of palmitoylation changes among DPPs. For example, palmitoylation levels of DDPs, such as AGPAT1 (1-acylglycerol-3-phosphate O-acyltransferase 1), PKP2 (plakophilin 2), TMEM231 (transmembrane protein 231), SLC7A2 (solute carrier family 7 member 2), CLCN2 (chloride voltage-gated channel 2), and F2R (protease-activated receptors), decreased in both T24S and T24R cells after 2-BP treatment (Figure 5G). In

contrast, DPPs, like PPP2R1B (protein phosphatase 2 scaffold subunit A beta), CSRP1 (cysteine and glycine rich protein 1), SHB (SH2 domain containing adaptor protein B), were decreased only in T24R cells following 2-BP treatment (Figure 5G). Collectively, these findings suggest that a variety of palmitoylation mechanisms may play a role in the regulation of protein palmitoylation. In both T24S and T24R cells, there were noticeable common biological processes affected by palmitoylation inhibition, including protein localization and fatty acid beta-oxidation.




Figure 3. Identification of differentially palmitoylated proteins (DPPs). (A) Diagram showing 180 up and 326 downregulated DPPs in T24R cells. (B) Volcano plot shows all putative palmitoylated proteins. Red, upregulated DPPs in T24R cells compared to T24S (n=180). Blue, downregulated DPPs in T24R cells compared to T24S (n=326). (C) Top 10 most and least DDPs among known palmitoylated proteins.




Figure 4. Biological enrichment of DPPs between T24R and T24S cells. (A) Bar graph shows top 10 biological processes enriched by DPPs in T24R cells compared to T24S. **(B-C)** Bar graphs show enriched biological processes upregulated **(B)** and downregulated by DPPs in T24R cells **(C)**. **(D-E)** Doughnut charts visualize the proportion of the numbers of up (outside donut) and downregulated (inside donut) DPPs in the enriched molecular functions **(D)** and cellular compartments **(E)**.

ACSS2 inhibition decreases fatty acid synthesis and changes palmitoylation of proteins in BC cells

Our previous study extensively investigated and demonstrated the link between lipid production and cisplatin resistance. The total lipid levels in T24R cells were significantly higher than those in T24S cells (~170%) [52]. In T24R cells, expression of several lipid metabolism-related proteins, such as ACC (acetyl-CoA carboxylase), FASN, and ACSS2 (acyl-CoA

synthetase short chain family member 2), was found to be increased. Since FASN is a key player in palmitate synthesis, the influence of palmitate levels and cholesterol concentration was examined in the context of cisplatin resistance. Experimental results from our previous [53] and current study show increased palmitate, cholesterol, and lipid production in T24R cells compared to T24S **(Figure 6A and 6B)**. Our group previously found that ACSS2 inhibition decreased the *de novo* synthesis of fatty acid by more than 60% in T24R cells, but not in T24S [51].

Table 1. Enriched biological process of DPPs

	GOBPs	Gene count	P-value	Genes
	cell adhesion	29	0.006294	ARHGAP5, ATP1B1, CASP8, CSRP1, DSP, CYR61, LDHA, BCAM, ME1, NCAM1, NEO1, PKP2, PLCB3, PLXNB3, PSMB10, SHB, SHC1, STK10, TPBG, SCARF1, NRP2, ME3, TMOD3, OLA1, ERBIN, ESYT2, EFHD2, VASN, MICA.
T24R vs T24S Up	lipid metabolic process	27	0.000834	ACAA1, ACACA, ALDH1A3, ALDH3A2, CREBBP, AKR1C1, DHCR7, GM2A, HMGS1, CYR61, PITPNA, PLCB3, ABCD3, SCD, ALDH5A1, SCARF1, ACAA2, AGPAT1, DDX20, PTGR1, ACSL5, NANS, DOLP1, MBOAT7, PTPMT1, CERS6, IAH1.
	oxidation-reduction process	26	0.000018	ACAA1, ALDH1A3, ALDH3A2, ALDOC, COX15, AKR1C1, DHCR7, LDHA, ME1, NDUFS8, PGD, ABCD3, PYGB, SCD, SPR, ALDH5A1, ACAA2, ME3, PTGR1, PRDX5, KDM3A, SQOR, NXN, VKORC1L1, QSOX2, HEPHL1.
	cell adhesion	45	0.005795	CD59, CLPTM1, COL6A1, DNM2, DSC3, HDLBP, HSPB1, JUP, LAMC1, LGALS1, LRP6, LYN, TACSTD2, MCAM, NCAM2, PDPK1, PNN, PODXL, PRKCD, PSEN1, RANGAP1, ROBO1, RPL22, S100A11, SLC9A1, ZEB1, TGFB1, TGFB2, MAD1L1, RIPK2, TJP2, FLOT1, PACSIN2, CLASP2, MPRIIP, ICOSLG, NECTIN3, TES, BAIAP2L1, JAM2, EPS8L2, VMP1, CD99L2, ANTXR1, PHLDB2.
T24R vs T24S Down	ion transport	47	0.000072	ABCD1, CLCN2, CLCN7, CLN3, COX4I1, DNM2, DPYSL2, STOM, F2R, GLS, LYN, ABCC1, P2RX4, PDPK1, PKD2, PLP2, PSEN1, PSEN2, SLC6A9, SLC7A2, SLC9A1, SLC12A2, SLC25A1, SNAP25, TGFB1, SLC39A7, SLC43A1, SLC5A6, SLC16A3, TMEM63A, SLC12A7, SERINC3, SLC39A14, CALHM2, TRPV2, SLC38A2, MCOLN1, SERINC1, SLC26A6, TTYH3, SLC38A1, MCU, ORAI3, SLC46A1, NIP1, SLC9B2, CALHM5.
	anion transport	25	0.000003	ABCD1, CLCN2, CLCN7, CLN3, DPYSL2, GLS, ABCC1, P2RX4, PSEN1, SLC6A9, SLC7A2, SLC12A2, SLC25A1, SNAP25, SLC43A1, SLC5A6, SLC16A3, SLC12A7, SERINC3, SLC38A2, SERINC1, SLC26A6, TTYH3, SLC38A1, SLC46A1.

Given these findings, we speculated that increased palmitate and cholesterol production via ACSS2 in T24R promotes changes in palmitoylation status of specific proteins; thereby, contributing to cisplatin resistance. An LC-MS/MS approach was used to determine if ACSS2 inhibition perturbs palmitoylation status of proteins in T24S and T24R cells. In T24S cells, bioinformatic analysis revealed 255 DPPs, of which 80 were upregulated and 175 were downregulated (Figure 6C). The volcano plot in Figure 6D shows the downregulated proteins and their palmitoylation levels following ACSS2 inhibition treatment. The biological processes of these DPPs include ion transport, cellular homeostasis, cell adhesion, cell migration, and proliferation (Figure 6E). In T24R cells, ACSS2 inhibition led to 98 downregulated DDPs (Figure 6F and 6G). The downregulated DDPs are involved in immune response related biological processes, such as regulation of response to external stimulus, homeostatic process, inflammatory response, chemotaxis, leukocyte migration, and regulation of cell proliferation (Figure 6H).

FASN palmitoylation and PD-L1 expression in BC

The palmitoylation of FASN was first validated because its link to lipid metabolism is well established in many cancer types, including BC [33,36,54,55]. FASN was found to be more palmitoylated in T24R cells compared to T24S. Because palmitoylation often contributes to increased protein stability and eventual upregulated expression, FASN expression could be associated with BC cisplatin resistance. We next tested a possible link between increased lipid production and palmitoylation with cisplatin resistance in BC.

At baseline, T24R cells were found to express modest but greater levels of FASN expression than

T24S (Supplementary Figure 2). The LB-ABE method was used to validate whether FASN was palmitoylated in BC cells. FASN palmitoylation levels were increased in T24R cells compared to T24S (Figure 7A). There were more palmitoylated FASN proteins detected as well. Palmitoylation inhibition by 2-BP repressed FASN expression in a dose-dependent manner in both T24S and T24R cells (Figure 7B). This implies that FASN is palmitoylated in BC cells, and the increase in palmitoylation of FASN is likely associated with cisplatin resistance in BC.

Additional experiments were conducted to support the FASN palmitoylation data using commercial palmitoylation protein assay kits, as described in the Methods. These kits are based on similar enrichment principles as our own. After palmitoylation enrichment, the total palmitoylation levels were almost identical in T24R and T24S cells. However, after treatment with 2-BP, the total palmitoylated proteins were significantly reduced in T24S cells compared to T24R, which had partial remaining palmitoylated proteins. Further data using western blot analysis showed that palmitoylated FASN was increased in T24R cells compared to T24S (Figure 7C, palmitoylated FASN panel). PD-L1 was also found to be palmitoylated in both T24S and T24R cells. Palmitoylation levels of PD-L1 were greater in T24R cells with or without 2-BP treatment (Figure 7C, palmitoylated PD-L1 panel). PD-L1 expression was determined to be approximately 15-fold greater in T24R cells compared to T24S (Figure 7D). When palmitoylation was inhibited by 2-BP, PD-L1 expression was significantly reduced in both T24R and T24S cells (Figure 7D). Although 2-BP abolished PD-L1 palmitoylation completely, it was not able to effectively suppress PD-L1 palmitoylation in T24R cells.




Figure 5. Effects of palmitoylation inhibition in T24S and T24R cells (A) Pie chart depicts the number of up and downregulated DPPs by palmitoylation inhibitor treatment in T24S cells. **(B)** Volcano plot shows the distribution of the DPPs with \log_2 ratio of palmitoylation inhibitor treated and untreated T24S cells (x-axis) and statistical significance (y-axis). **(C)** Bar plot shows downregulated biological processes in T24S cells in response to the inhibitor treatment. **(D)** Pie chart depicts the number of up and downregulated DPPs by palmitoylation inhibitor treatment in T24R cells. **(E)** Volcano plot shows the distribution of the DPPs with \log_2 ratio of inhibitor treated and untreated T24R cells (x-axis) and statistical significance (y-axis). **(F)** Bar plot shows downregulated biological processes in T24R cells in response to the inhibitor treatment. **(G)** Palmitoylated protein abundance with or without palmitoylation inhibitor in T24S and T24R cells. Examples of palmitoyl-proteins that have different effects on the treatment of

palmitoylation inhibitor are shown. **(Top)** Three proteins exhibit higher expression in T24R cells compared to T24S and have significant downregulation after inhibitor treatment in both. **(Middle)** Three proteins are significantly higher in T24S cells compared to T24R and have significant downregulation in both. **(Bottom)** Three proteins are significantly higher in T24R cells compared to T24S and have significant downregulation only in T24R.




Figure 6. Effects of ACSS2 inhibitor in T24S and T24R. **(A)** Palmitate concentration in T24S and T24R cells. **(B)** Cholesterol levels were compared in T24S and T24R cells. **(C)** Pie chart depicts the number of up (n=175) and downregulated DPPs (n=80) following ACSS2 inhibitor treatment in T24S cells. **(D)** Volcano plot shows the distribution of the DPPs with log₂ ratio of ACSS2 inhibitor treated and untreated T24S cells (x-axis) and statistical significance (y-axis). **(E)** Bar plot shows downregulated biological processes in T24S cells in response to ACSS2 inhibitor treatment. **(F)** Pie chart depicts the number of up (n=164) and downregulated DPPs (n=98) following ACSS2 inhibitor treatment in T24R cells. **(G)** Volcano plot shows the distribution of the DPPs with log₂ ratio of ACSS2 inhibitor treated and untreated T24R cells (x-axis) and statistical significance (y-axis). **(H)** Bar plot shows downregulated biological processes in T24R cells in response to ACSS2 inhibitor treatment.

Next, the effects of FASN inhibition on BC-specific palmitoylated proteins was examined. T24S and T24R cells were treated with orlistat. This reduced PD-L1 protein expression in both T24R and T24S cells (**Figure 7E**), suggesting that FASN activity likely regulates PD-L1 palmitoylation and stability. It

was confirmed that there were no cytotoxic effects of orlistat within the conditions used, based on additional analysis showing that there were no observed changes in cell viability in response to orlistat in both T24S and T24R cells (**Figure 7F**).




Figure 7. (A) Validation of FASN palmitoylation in T24S and T24R cells. Western blot analysis was performed using palmitoylation-enriched proteins. The same amount of proteins was used as starting materials (input). (B) FASN protein expression is downregulated by palmitoylation inhibition. Vehicle-treated cells acted as controls. (C) Further validation of FASN palmitoylation using a commercial kit. PD-L1 was also palmitoylated both in T24S and T24R cells. (D) Palmitoylation inhibition by 25 μM 2-BP treatment dramatically reduced protein expression of PD-L1 and FASN. Western blot analysis of FASN and PD-L1 protein expression from cells exposed to either 2-BP or vehicle control. (E) Expression of PD-L1 decreased in response to 50 μM orlistat treatment. (F) Cell viability assays on the effects of orlistat at varying time points or concentrations did not show any significant difference. Differences in cell viability, in which vehicle acted as control, was determined by t-test. Data are representative of at least three different experiments. Error bars denote SEM. *, **, and n.s. stand for $p < 0.01$, $p < 0.05$, and $p \geq 0.05$, respectively.

Discussion

S-palmitoylation (S-acylation) is the enzymatic addition of a fatty acid (acyl) group, such as palmitate, onto cysteine residues of a protein via thioester linkage, which is catalyzed by palmitoyltransferases and depalmitoyltransferases [56]. Many protein substrates can be palmitoylated by more than one DHHC enzyme with certain DHHC-substrate

specificity. DHHCs may act as a functional heterodimer, which may affect their enzymatic activities. S-palmitoylation is a powerful regulatory mechanism for a number of cellular processes, including signal transduction, protein turnover, vesicle fusion, and cell-cell interactions. Dysfunctions can lead to cancer, cardiovascular disease, and neurological disorders [57-59]. The reversible modification of cysteine residues by thioester formation with palmitate by the addition of a C16:0

carbon palmitoyl moiety is an abundant lipid post-translational modification. This addition of palmitate enhances a protein's affinity to the membrane, directs its distribution in membrane micro-domains, and mediates protein-protein interactions, trafficking, stability, and aggregation state. There is an intriguing potential connection between alterations in the metabolome and mitochondrial regulation. In addition, post-translational lipid modification targets and shuttles proteins between the cytosol and lipid raft within the plasma and mitochondrial membranes. Palmitoylation is known to play active roles in the sorting and trafficking of many proteins, and fluctuations in palmitoylation may contribute to signaling outcomes. S-palmitoylation has been observed in many ER and mitochondrial proteins, suggesting an intriguing potential connection between metabolic lipids and mitochondrial regulation [60]. However, it is unknown whether or how mitochondrial S-palmitoylation is regulated in the context of resistance against chemotherapy [16,61-63].

Our palmitoyl-proteomics approach detected a total of 25,598 peptides and 3,695 putative palmitoylated proteins in either T24S or T24R BC cells. The further defined 506 DDPs included 180 upregulated and 326 downregulated palmitoylated proteins in T24R cells. Our results also uncovered a novel molecular mechanism of palmitoylation, which demonstrates that protein palmitoylation of putative candidate proteins, is linked with responsiveness to chemotherapy, such as cisplatin. In this study, our palmitoylated protein-enriched proteomics profiling comparing cisplatin-resistant and sensitive BC cells showed that FASN is critical for protein palmitoylation in cisplatin-resistant cells. FASN plays an important role in synthesis of palmitate, which is both a precursor for fatty acids and the acyl group that is added to cysteine residues during palmitoylation [64]. Therefore, it is logical to infer that overexpression of FASN is associated with increased protein palmitoylation, which then contributes to worse prognoses in certain cancers [65]. Furthermore, a recent study found that FASN mediates EGFR palmitoylation in EGFR-mutated chemo-resistant non-small cell lung cancer [32].

We found that FASN expression and palmitoylation may lead to increased PD-1 expression and palmitoylation. PD-L1, a T cell regulatory molecule that is expressed on the surface of tumor and tumor-infiltrating immune cells, was also found to be highly palmitoylated in cisplatin-resistant BC cells, compared to isogenic control cells [66]. Activation of the pathway inhibits the activation of cytotoxic T lymphocytes and is one of the main

methods through which tumor cells evade immune responses [67]. Antibodies targeting PD-L1 are known to benefit overall survival in BC, and several agents have received accelerated approval from the FDA for treatment [68]. In addition to being a clinical target, PD-L1 has also been shown to be a significant clinical predictor for stage and treatment response in BC [69]. It has been previously shown that PD-L1 is palmitoylated via a covalent attachment of palmitic acid to its 272 cysteine residue for stability [70]. Although the effects of PD-L1 palmitoylation has not been thoroughly examined in the context of BC, previous studies have shown that palmitoylation stabilizes PD-L1 and promotes tumor growth in other cancer types, such as breast cancer [71], melanoma, and BC. Based on this prior evidence, exploring the influence of PD-L1 palmitoylation in BC progression and aggression presents a promising opportunity.

There are limitations in this study. Although there are ongoing studies in our laboratory, this study did not provide evidence to demonstrate whether inhibition of both FASN and PD-L1 may have synergistic inhibitory effects on cancer progression. These alternative hypotheses await further investigation. Currently, the most widely used palmitoylation inhibitor, 2-BP, a non-metabolizable palmitate analog, elicits pleiotropic effects. However, no inhibitory drugs targeting palmitoylation with high-affinity and specificity are available. There is an urgent need to identify specific, high-affinity inhibitors of protein palmitoylation for basic research and therapeutic intervention based on palmitoylation. Thus, much work remains to be developed on the specific and high affinity inhibitors of protein palmitoylation that can be applied as therapeutic strategies designed for overcoming cisplatin resistance in BC. In this study, we did not focus on the specific enzymes that catalyze palmitoylation of PD-L1. Further analysis on how palmitoylases and depalmitoylases, such as ZDHHC and APT/PPT, control PD-L1 palmitoylation and activity and contribute to activation of oncogenic pathways is warranted. Additional exploration of these mechanisms is necessary to clarify how PD-L1 is trafficked in the cell and how its activity is controlled in the context of cisplatin resistance.

Supplementary Material

Supplementary figures and tables.

<http://www.ijbs.com/v16p2490s1.pdf>

Competing Interests

The authors have declared that no competing interest exists.

References

- Noon AP, Catto JW. Bladder cancer in 2012: Challenging current paradigms [Review]. *Nat Rev Urol*. 2013 Feb;10(2):67-8.
- Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis [Review]. *Urology*. 2005; 66(6 Suppl 1):4-34.
- Kim J, Jahng WJ, Di Vizio D, et al. The phosphoinositide kinase PIKfyve mediates epidermal growth factor receptor trafficking to the nucleus [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. *Cancer Res*. 2007 Oct 1;67(19):9229-37.
- Kamat AM, Hegarty PK, Gee JR, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers [Consensus Development Conference Practice Guideline Review]. *Eur Urol*. 2013 Jan;63(1):4-15.
- Gakis G, Efstathiou J, Lerner SP, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder [Consensus Development Conference Practice Guideline Review]. *Eur Urol*. 2013 Jan;63(1):45-57.
- Sternberg CN, Bellmunt J, Sonpavde G, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings [Consensus Development Conference Practice Guideline Review]. *Eur Urol*. 2013 Jan;63(1):58-66.
- Masui K, Cavenee WK, Mischel PS. mTORC2 in the center of cancer metabolic reprogramming [Review]. *Trends Endocrinol Metab*. 2014 May 21.
- Masui K, Cavenee WK, Mischel PS. mTORC2 dictates Warburg effect and drug resistance [Editorial]. *Cell Cycle*. 2014 Apr 1;13(7):1053-4.
- Phan LM, Yeung SC, Lee MH. Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies [Review]. *Cancer Biol Med*. 2014 Mar;11(1):1-19.
- Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel [Research Support, Non-U.S. Gov't Review]. *Cancer Cell*. 2008 Jun;13(6):472-82.
- Huang Z, Lin L, Gao Y, et al. Bladder cancer determination via two urinary metabolites: a biomarker pattern approach. *Mol Cell Proteomics*. 2011 Oct;10(10):M111 007922.
- Jin X, Yun SJ, Jeong P, et al. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics. *Oncotarget*. 2014 Mar 30;5(6):1635-45.
- Amoedo ND, Obre E, Rossignol R. Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy. *Biochim Biophys Acta*. 2017 Aug;1858(8):674-685.
- Schug ZT, Peck B, Jones DT, et al. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. *Cancer Cell*. 2015 Jan 12;27(1):57-71.
- Huang Z, Zhang M, Plec AA, et al. ACS2 promotes systemic fat storage and utilization through selective regulation of genes involved in lipid metabolism. *Proc Natl Acad Sci U S A*. 2018 Oct 2;115(40):E9499-E9506.
- Linder ME, Deschenes RJ. Palmitoylation: policing protein stability and traffic. *Nat Rev Mol Cell Biol*. 2007 Jan;8(1):74-84.
- Resh MD. Palmitoylation of proteins in cancer. *Biochem Soc Trans*. 2017 Apr 15;45(2):409-416.
- Tabaczar S, Czogalla A, Podkalicka J, et al. Protein palmitoylation: Palmitoyltransferases and their specificity. *Exp Biol Med (Maywood)*. 2017 Jun;242(11):1150-1157.
- Valdez-Taubas J, Pelham H. Swf1-dependent palmitoylation of the SNARE Tlg1 prevents its ubiquitination and degradation. *EMBO J*. 2005 Jul 20;24(14):2524-32.
- Levental I, Grzybek M, Simons K. Greasing their way: lipid modifications determine protein association with membrane rafts. *Biochemistry*. 2010 Aug 3;49(30):6305-16.
- Sophasan S, Chatsudthipong V, Kraisaewekwisai S. Kidney pressures after the release of 24 hours of bilateral ureteral ligation in the rat. *J Urol*. 1982 Nov;128(5):1081-6.
- Akimzhanov AM, Boehning D. Rapid and transient palmitoylation of the tyrosine kinase Lck mediates Fas signaling. *Proc Natl Acad Sci U S A*. 2015 Sep 22;112(38):11876-80.
- Cao N, Li JK, Rao YQ, et al. A potential role for protein palmitoylation and zDHHCl6 in DNA damage response. *BMC Mol Biol*. 2016 May 10;17(1):12.
- Chen X, Ma H, Wang Z, et al. EZH2 Palmitoylation Mediated by ZDHHCl5 in p53-Mutant Glioma Drives Malignant Development and Progression. *Cancer Res*. 2017 Sep 15;77(18):4998-5010.
- Coleman DT, Gray AL, Kridel SJ, et al. Palmitoylation regulates the intracellular trafficking and stability of c-Met. *Oncotarget*. 2016 May 31;7(22):32664-77.
- Murphy J, Kolandaivelu S. Palmitoylation of Progressive Rod-Cone Degeneration (PRCD) Regulates Protein Stability and Localization. *J Biol Chem*. 2016 Oct 28;291(44):23036-23046.
- Noland CL, Gierke S, Schnier PD, et al. Palmitoylation of TEAD Transcription Factors Is Required for Their Stability and Function in Hippo Pathway Signaling. *Structure*. 2016 Jan 5;24(1):179-186.
- Yang W, Di Vizio D, Kirchner M, et al. Proteome scale characterization of human S-acylated proteins in lipid raft-enriched and non-raft membranes. *Mol Cell Proteomics*. 2010 Jan;9(1):54-70.
- Zhou B, Wang Y, Yan Y, et al. Low-Background Acyl-Biotinyl Exchange Largely Eliminates the Coisolation of Non-S-Acylated Proteins and Enables Deep S-Acylproteomic Analysis. *Anal Chem*. 2019 Aug 6;91(15):9858-9866.
- Zhou B, Wang Y, Yan Y, Mariscal J, et al. Low-background acyl-biotinyl exchange largely eliminates the co-isolation of non-S-acylated proteins and enables deep S-acylproteomic analysis. *bioRxiv*. 2009;588988
- Li J, Dong L, Wei D, et al. Fatty acid synthase mediates the epithelial-mesenchymal transition of breast cancer cells. *Int J Biol Sci*. 2014;10(2):171-80.
- Ali A, Levantini E, Teo JT, et al. Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer. *EMBO Mol Med*. 2018 Mar;10(3).
- Abdelrahman AE, Rashed HE, Elkady E, et al. Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer. *Ann Diagn Pathol*. 2019 Apr;39:42-52.
- Chen Q, Chong T, Yin J, et al. Molecular events are associated with resistance to vinblastine in bladder cancer. *Cell Mol Biol (Noisy-le-grand)*. 2015 May 8;61(2):33-8.
- Sugino T, Baba K, Hoshi N, et al. Overexpression of fatty acid synthase in human urinary bladder cancer and combined expression of the synthase and Ki-67 as a predictor of prognosis of cancer patients. *Med Mol Morphol*. 2011 Sep;44(3):146-50.
- Jiang B, Li EH, Lu YY, et al. Inhibition of fatty-acid synthase suppresses P-AKT and induces apoptosis in bladder cancer. *Urology*. 2012 Aug;80(2):484 e9-15.
- Kim WT, Kim J, Yan C, et al. S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy. *Annals of oncology : official journal of the European Society for Medical Oncology*. 2014 May;25(5):974-9.
- Wisniewski JR, Zougman A, Nagaraj N, et al. Universal sample preparation method for proteome analysis. *Nat Methods*. 2009 May;6(5):359-62.
- Zhou B, Yan Y, Wang Y, et al. Quantitative proteomic analysis of prostate tissue specimens identifies deregulated protein complexes in primary prostate cancer. *Clin Proteomics*. 2019;16:15.
- Cox J, Neuhauser N, Michalski A, et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. *J Proteome Res*. 2011 Apr 1;10(4):1794-805.
- Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat Biotechnol*. 2008 Dec;26(12):1367-72.
- Bolstad BM, Irizarry RA, Astrand M, et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. *Bioinformatics*. 2003 Jan 22;19(2):185-93.
- Shin J, Kim M, Jung HJ, et al. Characterization of developmental defects in the forebrain resulting from hyperactivated mTOR signaling by integrative analysis of transcriptomic and proteomic data. *Sci Rep*. 2017 Jun 6;7(1):2826.
- Hwang D, Rust AG, Ramsey S, et al. A data integration methodology for systems biology. *Proc Natl Acad Sci U S A*. 2005 Nov 29;102(48):17296-301.
- Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc*. 2009;4(1):44-57.
- Mi H, Huang X, Muruganujan A, et al. PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. *Nucleic Acids Res*. 2017 Jan 4;45(D1):D183-D189.
- Szklarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. *Nucleic Acids Res*. 2017 Jan 4;45(D1):D362-D368.
- Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome research*. 2003 Nov;13(11):2498-504.
- Shahid M, Lee MY, Yeon A, et al. Menthol, a unique urinary volatile compound, is associated with chronic inflammation in interstitial cystitis. *Sci Rep*. 2018 Jul 18;8(1):10859.

50. Choi DY, You S, Jung JH, et al. Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment. *Proteomics*. 2014 Aug;14(16):1845-56.
51. Wen H, Lee S, Zhu WG, et al. Glucose-derived acetate and ACS2 as key players in cisplatin resistance in bladder cancer. *Biochim Biophys Acta Mol Cell Biol Lipids*. 2019 Mar;1864(3):413-421.
52. Blanc M, David FPA, van der Goot FG. SwissPalm 2: Protein S-Palmitoylation Database. *Methods Mol Biol*. 2019;2009:203-214.
53. Lee MY, Yeon A, Shahid M, et al. Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance. *Oncotarget*. 2018 Mar 29;17(1):13231-13243.
54. Kim J, Kim WJ, Liu Z, et al. The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer. *Cell Cycle*. 2012 Mar 15;11(6):1123-30.
55. Tao T, Su Q, Xu S, et al. Down-regulation of PKM2 decreases FASN expression in bladder cancer cells through AKT/mTOR/SREBP-1c axis. *J Cell Physiol*. 2019 Mar;234(3):3088-3104.
56. Shen LF, Chen YJ, Liu KM, et al. Role of S-Palmitoylation by ZDHHC13 in Mitochondrial function and Metabolism in Liver. *Sci Rep*. 2017 May 19;7(1):2182.
57. Yeste-Velasco M, Linder ME, Lu YJ. Protein S-palmitoylation and cancer. *Biochim Biophys Acta*. 2015 Aug;1856(1):107-20.
58. Fuller W, Reilly L, Hilgemann DW. S-palmitoylation and the regulation of NCX1. *Channels (Austin)*. 2016;10(2):75-7.
59. Napoli E, Song G, Liu S, et al. Zdhhc13-dependent Drp1 S-palmitoylation impacts brain bioenergetics, anxiety, coordination and motor skills. *Sci Rep*. 2017 Oct 16;7(1):12796.
60. Dallavilla T, Abrami L, Sandoz PA, et al. Model-Driven Understanding of Palmitoylation Dynamics: Regulated Acylation of the Endoplasmic Reticulum Chaperone Calnexin. *PLoS Comput Biol*. 2016 Feb;12(2):e1004774.
61. Ko PJ, Dixon SJ. Protein palmitoylation and cancer. *EMBO Rep*. 2018 Oct;19(10).
62. Wang W, Runkle KB, Terkowski SM, et al. Protein Depalmitoylation Is Induced by Wnt5a and Promotes Polarized Cell Behavior. *J Biol Chem*. 2015 Jun 19;290(25):15707-16.
63. Levental I, Lingwood D, Grzybek M, et al. Palmitoylation regulates raft affinity for the majority of integral raft proteins. *Proc Natl Acad Sci U S A*. 2010 Dec 21;107(51):22050-4.
64. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. *Nat Rev Cancer*. 2007 Oct;7(10):763-77.
65. Piyathilake CJ, Frost AR, Manne U, et al. The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung. *Hum Pathol*. 2000 Sep;31(9):1068-73.
66. Gao Y, Li S, Xu D, et al. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma. *Chin J Cancer*. 2017 Jul 29;36(1):61.
67. Huang Y, Zhang SD, McCrudden C, et al. The prognostic significance of PD-L1 in bladder cancer. *Oncol Rep*. 2015 Jun;33(6):3075-84.
68. Aggen DH, Drake CG. Biomarkers for immunotherapy in bladder cancer: a moving target. *J Immunother Cancer*. 2017 Nov 21;5(1):94.
69. Wu CT, Chen WC, Chang YH, et al. The role of PD-L1 in the radiation response and clinical outcome for bladder cancer. *Sci Rep*. 2016 Jan 25;6:19740.
70. Gu W, Wang L, Wu Y, et al. Undo the brake of tumour immune tolerance with antibodies, peptide mimetics and small molecule compounds targeting PD-1/PD-L1 checkpoint at different locations for acceleration of cytotoxic immunity to cancer cells. *Clin Exp Pharmacol Physiol*. 2019 Feb;46(2):105-115.
71. Yang Y, Hsu JM, Sun L, et al. Palmitoylation stabilizes PD-L1 to promote breast tumor growth. *Cell Res*. 2019 Jan;29(1):83-86.